UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
FORM 8-K
----------------
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 22, 2004
ATHEROGENICS, INC.
----------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
GEORGIA 0-31261 58-2108232
------- ------- ----------
(State or other (Commission (I.R.S. Employer
jurisdiction File Number) Identification Number)
of incorporation)
8995 Westside Parkway
Alpharetta, GA 30004
(Address of principal executive offices)
----------------------------------------
Registrant's telephone number, including area code (678) 336-2500
------------------
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
Exhibits.
The following exhibit is furnished as part of this current report on
Form 8-K.
Exhibit No. Description
----------- -----------
99.1 - Press Release dated April 22, 2004
Item 12. Results of Operations and Financial Condition.
On April 22, 2004, AtheroGenics, Inc. issued a press release to report
the company's financial results for the quarter ended March 31, 2004. A copy
of the press release is attached to this current report on Form 8-K as
Exhibit 99.1.
--------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ATHEROGENICS, INC.
Date: April 22, 2004 /s/MARK P. COLONNESE
--------------------------------
Mark P. Colonnese
Senior Vice President of Finance
and Administration and Chief
Financial Officer
--------------------
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 - Press Release dated April 22, 2004